BLLN (BillionToOne) 12-1 Month Momentum %: N/A% (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLLN BillionToOne Inc BLLN
15 GF Score
Price $95.05
! 4 Warning Signs
View Full Analysis

What is BillionToOne 12-1 Month Momentum %?

BillionToOne BLLN -0.25% 15 12-1 Month Momentum % is N/A% as of Aug. 21, 2026. GuruFocus rates BLLN with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, BillionToOne ranks worse than 471697.64% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-21), BillionToOne's 12-1 Month Momentum % is N/A%.

The industry rank for BillionToOne's 12-1 Month Momentum % or its related term are showing as below:

BLLN's 12-1 Month Momentum % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -13.265
* Ranked among companies with meaningful 12-1 Month Momentum % only.

BillionToOne  (NAS:BLLN) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

BillionToOne 12-1 Month Momentum % Related Terms

BLLN
15GF Score
BillionToOne Inc BLLN
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BillionToOne  (NAS:BLLN) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of N/A% mean?
BillionToOne (BLLN) has a 12-1 Month Momentum % of N/A% as of Aug. 21, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on BillionToOne and its competitors. According to the industry distribution chart, BillionToOne ranks #999999 out of 212 companies in the Medical Diagnostics & Research industry.
Is BillionToOne's 12-1 Month Momentum % too high?
BillionToOne's current 12-1 Month Momentum % is N/A%. Based on the distribution chart, BillionToOne ranks #999999 out of 212 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, BillionToOne has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's 12-1 Month Momentum % compare to TWST and SHC?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #999999 out of 212 companies for 12-1 Month Momentum %. This places BillionToOne in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 12-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on BillionToOne and its competitors. BillionToOne's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current 12-1 Month Momentum % of N/A%. The current 12-1 Month Momentum % is N/A%. BillionToOne's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For BillionToOne (BLLN), the current 12-1 Month Momentum % is N/A% as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BillionToOne Business Description

Address 1035 O’Brien Drive, Menlo Park, CA, USA, 94025
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
15GF Score

Get the complete analysis for BLLN

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$95.05
Price